Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment

2021 Year in Review - Biosimilars - Biosimilars

The findings of a simulation modeling analysis demonstrate that conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb provides significant cost-savings, which could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy in patients with diffuse large B-cell lymphoma.

For the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN), 3 options are currently available: pegfilgrastim, pegfilgrastim with on-body injector (OBI), and its biosimilar pegfilgrastim-jmdb. A simulation modeling was performed to: (1) demonstrate that cost-savings generated from conversion of pegfilgrastim-OBI to pegfilgrastim-jmdb could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy and (2) to evaluate the economic impact of FN-related hospitalization costs due to pegfilgrastim-OBI failure.

A panel of 15,000 patients with cancer was used in the simulation modeling from the US payer perspective. The primary analyses included conversion rates of 10% to 100%. Simulations of budget-neutral expanded access to prophylaxis with pegfilgrastim-jmdb or to anticancer treatment of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL) were also performed. Adjusted analyses assumed OBI device failure rates of 1% to 7% and associated costs of FN-related hospitalization.

In a single cycle, the modeling showed that conversion from pegfilgrastim-OBI to pegfilgrastim-jmdb resulted in cost-savings ranging from $481,259 (10% conversion) to $4,812,585 (100% conversion). When modeled for 6 cycles at 100% conversion, the cost-savings were $28,857,510, which could be reallocated to provide 9191 additional doses of pegfilgrastim-jmdb or 4463 cycles of R-CHOP to patients with DLBCL.

The cost-savings further increased when adjusted for OBI failure and FN-related hospitalizations. Over 6 cycles, cost-savings ranged from $2,935,565 (10% conversion; 1% pegfilgrastim-OBI failure rate) to $32,236,499 (100% conversion; 7% pegfilgrastim-OBI failure rate). These cost-savings could provide expanded access to 943 doses of pegfilgrastim-jmdb or 454 doses of R-CHOP (10% conversion; 1% pegfilgrastim-OBI failure rate) or provide 10,261 doses of pegfilgrastim-jmdb or 4982 cycles of R-CHOP (100% conversion; 7% pegfilgrastim-OBI failure rate).

The findings of the simulation modeling support the conversion from pegfilgrastim to pegfilgrastim-jmdb to derive significant cost-savings, which is exponentially increased when pegfilgrastim-OBI failure and associated FN-related hospitalizations are also taken into account. The modeling also demonstrates that these cost-savings could be allocated on a budget-neutral basis to provide additional CIN/FN prophylaxis or antineoplastic treatment to more patients with DLBCL.

Source: McBride A, MacDonald K, Fuentes-Alburo A, Abraham I. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. J Med Econ. 2021;24:598-606

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: